Navigation Links
Ventana to collaborate with Boehringer Ingelheim on the development of companion diagnostic tests
Date:9/19/2013

TUCSON, Ariz. and INGELHEIM, Germany, Sept. 19, 2013 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, and Boehringer Ingelheim (BI) announced today that they have entered into an agreement to collaborate on the development of companion diagnostic tests for Boehringer Ingelheim oncology programs.

(Photo: http://photos.prnewswire.com/prnh/20130919/LA82369)

As part of the agreement, Ventana will utilize its immunohistochemistry technology platform, experience and expertise in companion diagnostic development and premarket approval (PMA) submissions to support Boehringer Ingelheim's personalized medicine healthcare strategies for cancer drug development.

Companion diagnostic tests provide information that aids physicians in choosing targeted treatments for their patients based on the expected best response to therapy. By integrating the development of companion diagnostic kits and drug candidates, Boehringer Ingelheim strives to yield cancer treatments with optimized benefit risk profiles.

"We are pleased that our commitment to enable Personalized Healthcare for patients worldwide was recognized by Boehringer Ingelheim when they selected Ventana to be a companion diagnostics development partner for their oncology programs," says Mara G. Aspinall, President, Ventana Medical Systems, Inc.

"We look forward to partnering with Ventana and accessing their significant capabilities and expertise in developing companion diagnostics that will complement our products to further advance the delivery of personalized healthcare solutions for patients," says Klaus Dugi, Corporate Senior Vice President, Medicine at Boehringer Ingelheim.

In addition to Boehringer Ingelheim, Ventana has worked with more than 45 biopharmaceutical partners over the past decade and is currently engaged in over 150 collaborative projects to develop and commercialize companion diagnostics globally.

About Ventana Medical Systems, Inc.

Ventana Medical Systems, Inc. ("VMSI") (SIX: RO, ROG; OTCQX: RHHBY), a member of the Roche Group, innovates and manufactures instruments and reagents that automate tissue processing and slide staining for cancer diagnostics. VENTANA solutions are used in clinical histology and drug development research laboratories worldwide. The company's intuitive, integrated staining, workflow management platforms, and digital pathology solutions optimize laboratory efficiencies to reduce errors, support diagnosis and inform treatment decisions for anatomic pathology professionals. Together with Roche, VMSI is driving Personalized Healthcare through accelerated drug discovery and the development of "companion diagnostics" to identify the patients most likely to respond favorably to specific therapies.  VENTANA and the VENTANA logo are trademarks of Roche. Visit http://ventana.com/ to learn more.

VMSI Media Relations
Jacqueline Bucher
Senior Director, Corporate Communications
Phone: 520-877-7288
e-mail: jacquie.bucher@ventana.roche.com

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates in 50 countries and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine. In 2012, Boehringer Ingelheim achieved net sales of about €14.2 billion. R&D expenditure in the business area Prescription Medicines corresponds to 22.5% of its net sales.

For more information, go to www.boehringer-ingelheim.com.

Media Contact
Dr. Reinhard Malin
Boehringer Ingelheim GmbH
Launch Products Core
Phone: +49 (6132) 77-90815
Email: reinhard.malin@boehringer-ingelheim.com

US Media Contact
Susan Holz
Public Relations
Phone: 203-798-4265
Email: susan.holz@boehringer-ingelheim.com


'/>"/>
SOURCE Ventana Medical Systems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Life Technologies to Collaborate with Merck Serono for Companion Diagnostics Development and Commercialization
2. QB3 to Collaborate with Johnson & Johnson Innovation on New Incubator
3. Freeslate Collaborates with Medicines for Malaria Venture to Advance Therapeutic for Treating Malaria
4. DuPont Tate & Lyle Bio Products Collaborates with RML Incorporated to Develop Bio-Based Solution for Personal Care Products
5. Research Foundations Collaborate To Fund Phase 1 Study Of Cancer Drug In Alzheimers Disease Patients
6. Sigma Life Science and the Culture Collections of Public Health England Collaborate to Distribute Cells and Cellular Extracts
7. DuPont Collaborates with Agricultural Educators to Reach More Students
8. DuPont Pioneer and Mendel Biotechnology, Inc. Collaborate to Improve Water Use Efficiency and Photosynthesis in Corn
9. Lockheed Martin and Nanyang Technological University to collaborate on nanotechnology
10. Elsevier and Kanazawa University in Japan Collaborate to Map Universitys Research Performance
11. Ceres and Syngenta to Collaborate on Sweet Sorghum Market Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... SAN DIEGO , Feb. 5, 2016 ... the region,s trusted information source for community, health and ... San Diego) will integrate to enhance care coordination ... people to the services they need and to better ... to improve care.   San Diego ...
(Date:2/4/2016)... New FDA action date of July 22, ... July 22, 2016   --> - ... - Lifitegrast has the potential to be the only ... signs and symptoms of dry eye disease in adults --> ... approved in the U.S. in the past decade indicated for the treatment of ...
(Date:2/4/2016)... SHENZHEN, China , Feb. 4, 2016 ... government, and various medical institutions attended a ceremony in ... provide integrative, personalized cell therapy in 2016. ... the "Shenzhen Clinical Translation Platform for Personalized Cell Therapy" ... Shenzhen Regional Cell Production Center, both subsidiaries of Beike ...
(Date:2/4/2016)... -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), a ... targeted antiviral therapies, announced today that it will present ... held February 8-9, 2016, at the Waldorf Astoria New ... Healthcare Conference, taking place in New York ... Sapirstein , Chief Executive Officer of ContraVir, will provide ...
Breaking Biology Technology:
(Date:2/4/2016)... 2016 The field of Human Microbiome ... most popular hubs of the biotechnology industry. While ... studies of human microbiota, have garnered a lot ... microbiome space has literally exploded in terms of ... report focuses on biomedical aspects of research, development, ...
(Date:2/3/2016)... 3, 2016 ... the "Emotion Detection and Recognition Market ... Others), Software Tools (Facial Expression, Voice Recognition ... Regions - Global forecast to 2020" ... http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced the addition ...
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 Technology ... service presents an analysis of the digital and computed ... Malaysia , and Indonesia ... current trends and market size, as well as regional ... by country and discusses market penetration and market attractiveness, ...
Breaking Biology News(10 mins):